Quest Pharmaceuticals

What Quest Pharmaceuticals does

Quest Pharmaceuticals P. Ltd. is a Nepal-based, privately-held pharmaceutical manufacturer and distributor established in 2001, headquartered in Kathmandu with manufacturing operations in Birgunj. The company holds WHO-Good Manufacturing Practice (WHO-GMP) certification for its production facility and achieved ISO 27001 certification for its Information Security Management System in January 2025. Its stated mission is to provide quality pharmaceutical products addressing Nepal's healthcare needs, with management citing a target aligned with Nepal's national objective of meeting 80% of domestic health requirements through local production by 2025.

Quest manufactures and markets a portfolio of more than 80 pharmaceutical products across multiple therapeutic categories, including antidiabetics (metformin, glimepiride, linagliptin, dapagliflozin combinations), cardiovascular agents (atorvastatin, rosuvastatin, telmisartan-amlodipine, ivabradine, torsemide), dermatology preparations (clobetasol, fusidic acid, isotretinoin formulations), neurology and psychiatry products (escitalopram, sertraline, paroxetine, levetiracetam, methylcobalamin combinations), gastroenterology products (omeprazole, esomeprazole, pantoprazole-domperidone, ursodeoxycholic acid), urology medications (dutasteride, silodosin, alfuzosin), and nutritional supplements (iron-polymaltose, vitamin D, calcium combinations). Production is formulation-based rather than active pharmaceutical ingredient (API) manufacturing, drawing on established molecules. The company reports manufacturing and distributing approximately 200 million units of medicines annually.

Quest operates a B2B go-to-market model, selling through a network of more than 100 distribution partners that supply pharmacies and medical stores across Nepal. End customers are patients receiving prescriptions; the company reports serving approximately 2 million patients annually and providing for nearly 4% of Nepal's total health needs. Pricing is determined through healthcare providers and pharmacies rather than published retail rates. Leadership includes founder and Managing Director Umesh Lal Shrestha (also elected FNCCI Vice-President in 2017) and Director Marketing S.P. Verma. The company reports 500+ employees and holds the FNCCI National Excellence Award in the Medium-Scale Industry category from 2014.

Name

Quest Pharmaceuticals

Legal name

Quest Pharmaceuticals P. Ltd.

Website

https://quest.com.np

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Short description

Quest Pharmaceuticals is a Nepal-based WHO-GMP certified generic drug manufacturer, established in 2001, producing 80+ pharmaceutical products across cardiovascular, diabetes, dermatology, and neurology categories. It distributes through 100+ partners to serve roughly 2 million patients annually across Nepal.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Pharmaceutical manufacturing
• Generic drug formulation
• Prescription medications
• Pharmaceutical distribution
• WHO-GMP manufacturing

Headquarters

HQ city

Birganj

HQ country

Nepal

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and marketing life-saving drugs and specialized medications to address urgent medical needs. Products are sold through distribution partners to pharmacies and healthcare providers across Nepal.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Quest Pharmaceuticals manufactures and markets a portfolio of 80+ branded pharmaceutical products across multiple therapeutic categories including antidiabetics, cardiovascular, dermatology, gastrointestinal, neurology, psychiatry, urology, and nutritional supplements. The company produces approximately 200 million units of medicines annually at its WHO-GMP certified manufacturing facility in Birgunj, distributing them through 100+ distribution partners to pharmacies and medical stores across Nepal.

Product overview

Quest Pharmaceuticals is a WHO-GMP and ISO 27001 certified pharmaceutical company from Nepal, established in 2001. The company manufactures and markets a comprehensive portfolio of pharmaceutical products across multiple therapeutic categories including analgesics, anti-infectives (antibiotics, antifungals, antivirals), cardiovascular drugs (antihypertensives, lipid-lowering agents, diuretics), diabetes medications (metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors), neurological and psychiatric treatments (anticonvulsants, antidepressants, antipsychotics), gastrointestinal products (PPIs, prokinetics), dermatological preparations (corticosteroids, antibiotics, antifungals), urology medications, nutritional supplements (vitamins, minerals, iron supplements, probiotics), and respiratory treatments. Key product lines include NEWRON (Methylcobalamin for neuropathic pain), LINTOR/LINTOR M SR (Linagliptin for diabetes), OZIN (Dapagliflozin for diabetes/heart failure), FUSID-B (dermatological cream), DART (Dutasteride for BPH), and various cardiovascular products like ASTAT, ROVASTIN, FENOCARD, and MYLOD AT. The company operates from Kathmandu with over 500 employees, serving over 2 million patients annually through 100+ distribution partners across Nepal.

Differentiator

Problem solved

Functional benefit

Products and services

• DART Dutasteride 0.5mg 5-alpha reductase inhibitor for treatment of Benign Prostate Hyperplasia (BPH).
• LINTOR Linagliptin DPP-4 inhibitor for type 2 diabetes glycemic control; available in 2.5mg and 5mg tablets.
• FUSID-B Fusidic Acid 2% + Betamethasone Valerate 0.1% cream for inflamed eczema with bacterial infection.
• DFER Cholecalciferol 60000 IU soft gelatin capsule for vitamin D deficiency treatment.
• LEVECAM Levetiracetam antiepileptic for partial, myoclonic, and tonic-clonic seizures.
• TRABET-S Halobetasol Propionate 0.05% + Salicylic Acid 3% ointment for eczema and psoriasis.
• HEPOXY Ursodeoxycholic acid tablets for gallstone dissolution and primary biliary cirrhosis.
• DEPNOX Paroxetine SSRI antidepressant for depression and related conditions.
• ACEMED SR 200 Aceclofenac 200mg sustained release NSAID for pain and inflammation.
• LINTOR M SR Linagliptin 2.5mg + Metformin SR 1000mg combination for type 2 diabetes.
• MYODIN Ivabradine selective If inhibitor for heart rate reduction in cardiac conditions.
• REXTER Torsemide loop diuretic for edema and hypertension treatment.
• ACNOM Isotretinoin capsules for severe nodular/conglobate acne treatment.
• QPDOM Pantoprazole 40mg + Domperidone 30mg capsules for acid-related diseases and nausea.
• LINTOR 5mg Linagliptin 5mg tablet for type 2 diabetes glycemic control.
• EVA Alpha Tocopheryl Acetate soft gelatin capsule for vitamin E deficiency treatment.
• CALSUP Calcium Carbonate with Vitamin D3 combination for calcium deficiency prevention and treatment.
• BIOXY Vitamin A+C+E+Betacarotene antioxidant supplement for early aging and heart diseases.
• IFOL Iron Polymaltose Complex & Folic Acid chewable tablet for hemoglobin increase.
• IFOL XT Ferrous Ascorbate & Folic Acid iron supplement for hemoglobin improvement.

Quantifiable outcome

• Serves 2 million patients annually
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• FNCCI (Federation of Nepalese Chambers of Commerce and Industries)minorOthersUmesh Lal Shrestha, Managing Director of Quest Pharmaceuticals, was elected Vice-President of FNCCI. FNCCI is the umbrella organization of businesses in Nepal, representing the country's business sector and promoting socio-economic development through private sector led economic growth. This represents the company's leadership role in Nepal's business community rather than a commercial partnership.

Scale indicators9 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Cipla: Indian multinational pharmaceutical giant with significant Nepal presence, broad generic and specialty portfolio, and substantially greater scale. Represents the largest competitive incumbent pressure on Quest's market share.
• Sun Pharmaceutical Industries: India's largest pharmaceutical company by revenue with strong Nepal distribution. Competes with Quest on price in cardiometabolic and chronic disease categories through local subsidiaries and distributors.

Direct peers

• Citizen Pharmaceuticals: Nepal-based pharmaceutical manufacturer producing generic formulations for the domestic market. Competes directly with Quest in similar therapeutic categories and pharmacy channels.
• Nepal Pharmaceuticals Lab: Established Nepalese pharmaceutical manufacturer producing branded generics distributed nationally. Competes with Quest across general medicine and chronic disease categories in the same domestic market.
• Time Pharmaceuticals: Nepal-based pharmaceutical manufacturer with WHO-GMP facility producing generic formulations. Comparable in scale, regulatory standing, and therapeutic breadth to Quest within Nepal.
• Lomus Pharmaceuticals: Nepal's largest domestic pharmaceutical manufacturer with a broad branded-generic portfolio. Most direct head-to-head competitor to Quest in Nepal's retail pharmacy channel across similar therapeutic categories.
• National Healthcare: Nepalese pharmaceutical company manufacturing and distributing generic medicines across multiple therapeutic areas. Operates in the same nationwide pharmacy distribution channel as Quest.

Regional players

• Alkem Laboratories: India-based pharmaceutical company with broad generic portfolio and export footprint across South Asia including Nepal. Comparable on branded-generic model and similar therapeutic coverage.
• Aristo Pharmaceuticals: Indian pharmaceutical manufacturer with branded-generic portfolio and presence in Nepal/South Asia. Competes on similar small-molecule generics including anti-infectives and chronic disease therapies.
• Micro Labs: Indian pharmaceutical company manufacturing branded generics across cardiology, diabetes, dermatology and other therapy areas with regional South Asia distribution reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/questpharmaceuticalsnepal
• LinkedInlinkedin.com/company/quest-pharmaceuticals-pvt-ltd-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quest Pharmaceuticals